<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647749</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/01</org_study_id>
    <nct_id>NCT02647749</nct_id>
  </id_info>
  <brief_title>Non-invasive Mapping of Rhythm Disorders</brief_title>
  <acronym>CARRY</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This current care protocol follows the biomedical research protocol entitled &quot;Non-invasive&#xD;
      mapping of the heart ECG high amplification&quot; that demonstrated the clinical value of&#xD;
      noninvasive Cardioinsight® mapping system.&#xD;
&#xD;
      Guide the management of patients hospitalized for cardiac rhythm radiofrequency ablation of&#xD;
      cardiac arrhythmias, implantation or programming of a pacemaker, or assess the risk of&#xD;
      serious arrhythmias or sudden death, with the currently used non-invasive mapping routine.&#xD;
      The results obtained with non-invasive mapping will be compared with those obtained with the&#xD;
      conventional method without non-invasive mapping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This current care protocol is for 3 groups of patients :&#xD;
&#xD;
        1. Role of mapping arrhythmias before radiofrequency ablation :&#xD;
&#xD;
           Radiofrequency ablation is a treatment of atrial or ventricular arrhythmias resistant to&#xD;
           drug treatment. The electrocardiogram does not allow a full diagnosis of arrhythmias and&#xD;
           it appears difficult to get a comprehensive and simultaneous view of cardiac activity&#xD;
           during invasive maps. The Investigators have demonstrated the feasibility of mapping&#xD;
           atrial fibrillation and its usefulness to guide radiofrequency ablation. The&#xD;
           non-invasive mapping would allow a better understanding of complex cardiac arrhythmias&#xD;
           mechanism (atrial fibrillation, ventricular tachycardia and ventricular fibrillation in&#xD;
           particular), would identify the arrhythmogenic sites and thus facilitate radiofrequency&#xD;
           ablation.&#xD;
&#xD;
        2. Optimizing the site of implantation of cardiac pacing leads and programming the&#xD;
           pacemaker:&#xD;
&#xD;
           The optimal position of the cardiac pacing leads may vary from one patient to another&#xD;
           and the current choice of implantation sites is essentially guided by imaging and does&#xD;
           not use power requirements because of the inadequacies of the ECG standard. The&#xD;
           Investigators have already demonstrated the usefulness of non-invasive mapping in the&#xD;
           selection of potential responders to cardiac resynchronization therapy. The non-invasive&#xD;
           mapping would study the cardiac electrical activation in order to determine the optimal&#xD;
           pacing sites and optimum programming according to each patient and thus improve the&#xD;
           clinical response to pacing.&#xD;
&#xD;
        3. Role diagnostic and prognostic for patients referred for evaluation of the risk of&#xD;
           occurrence of a serious rhythm disorder or sudden death :&#xD;
&#xD;
      The possibility to identify electrically abnormal areas either during the activation, or&#xD;
      during cardiac repolarization with the high-resolution ECG is an indication of myocardial&#xD;
      pathology that can be both unapparent on standard ECG and inaccessible to imaging techniques&#xD;
      (ultrasound, CT or MRI). It is likely that such electrical anomalies are early diagnostic&#xD;
      features of heart disease that will later be apparent. Such anomalies can also have an&#xD;
      adverse prognostic weight (risk of arrhythmias or sudden death) that can be corrected if it&#xD;
      is highlighted. Non-invasive mapping seems particularly important in patients with&#xD;
      unexplained symptoms by conventional tests (palpitations or discomfort - syncope). It will&#xD;
      also be applicable to patients with heart disease (myocardial infarction, cardiomyopathy) in&#xD;
      search of localized electrical disorders that can be an originating site of arrhythmia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia termination during ablation guided by the Cardioinsight® mapping system</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of dP/dT measurement between baseline and after implantation or programmation of a pacemaker guided by the Cardioinsight® mapping system</measure>
    <time_frame>Day 1</time_frame>
    <description>In mmHg/s</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the activation-recovery interval defined as the interval between a local depolarization time and repolarization time for patients referred for evaluation of the risk of occurrence of a serious rhythm disorder or sudden death</measure>
    <time_frame>Day 1</time_frame>
    <description>In ms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia recurrence at 1 year after ablation guided by the Cardioinsight® mapping system</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients referred for implantation or programming of a pacemaker: Comparison of 6 Minutes Walk Test performed before and 6 months after implantation and/or programmation guided by the Cardioinsight® mapping system</measure>
    <time_frame>Month 6</time_frame>
    <description>In meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients referred for implantation or programming of a pacemaker: Comparison of left ventricular ejection fraction performed before and 6 months after implantation and/or programmation guided by the Cardioinsight® mapping system</measure>
    <time_frame>Month 6</time_frame>
    <description>In percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of syncope, aborted sudden death or sudden death during follow-up for patients referred for evaluation of the risk of occurrence of a serious rhythm disorder or sudden death</measure>
    <time_frame>Year 1, year 4 at most</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Cardiac Rhythm Disorders</condition>
  <arm_group>
    <arm_group_label>Group 1 : Cardiac rythm radiofrequency ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Implantation or programming of a pacemaker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Risk of serious arrhythmias or sudden death</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Cardiac rythm radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retrospective recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : Implantation or programming of a pacemaker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retrospective recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : Risk of serious arrhythmias or sudden death</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retrospective recruitment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardioinsight® mapping system</intervention_name>
    <arm_group_label>Group 1 : Cardiac rythm radiofrequency ablation</arm_group_label>
    <arm_group_label>Group 1: Implantation or programming of a pacemaker</arm_group_label>
    <arm_group_label>Group 1: Risk of serious arrhythmias or sudden death</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional method without non-invasive mapping</intervention_name>
    <arm_group_label>Group 2 : Implantation or programming of a pacemaker</arm_group_label>
    <arm_group_label>Group 2 : Risk of serious arrhythmias or sudden death</arm_group_label>
    <arm_group_label>Group 2: Cardiac rythm radiofrequency ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oral agreement of the patient or of the holder of parental responsibility after&#xD;
             reading the informed consent form.&#xD;
&#xD;
          -  Patients with the following 3 conditions :&#xD;
&#xD;
          -  Ablation of drugs rebels arrhythmias.&#xD;
&#xD;
          -  Or implantation or programming of a pacemaker (pacemaker or defibrillator)&#xD;
&#xD;
          -  Or symptoms and / or cardiopathy with risk of sudden death.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Patients unable to give oral agreement.&#xD;
&#xD;
          -  Inconsistent patient's morphology with the establishment of the electrode jacket&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel HAÏSSAGUERRE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel HAÏSSAGUERRE, Pr</last_name>
    <email>michel.haissaguerre@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maider PIQUET</last_name>
    <email>maider.piquet@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel HAÏSSAGUERRE, Pr</last_name>
      <email>michel.haissaguerre@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maider PIQUET</last_name>
      <email>maider.piquet@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

